drugset / Trial / NCT00890318

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C

NCT00890318

Phase 1 Completed 32 enrolled Abbott
RandomizedSingle-groupQuadruple-blind

Summary

The purpose of this study is to determine multiple dose safety, tolerability and pharmacokinetics of ABT-072 under nonfasting conditions in healthy adult subjects, and to determine the effect of single dose administration of ketoconazole on steady state ABT-072 pharmacokinetics.

Timeline

Start
2009-04
Primary completion
2009-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject ABT-072 Small molecule 80 mg
Subject ABT-072 Small molecule 160 mg
Subject ABT-072 Small molecule 320 mg
Subject Ketoconazole Small molecule 400 mg